NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
Sacha Gnjatic(Tisch Hospital), Lloyd J. Old(Gynecologic Oncology Group), Yao‐Tseng Chen(Memorial Sloan Kettering Cancer Center), Gerd Ritter(Memorial Sloan Kettering Cancer Center), Elke Jäger(Krankenhaus Nordwest), Ali O. Güre(Memorial Sloan Kettering Cancer Center), Achim A. Jungbluth(Gynecologic Oncology Group), Alexander Knuth(National Center for Cancer Care and Research), Hiroyoshi Nishikawa(Immunité et Cancer)
Cited by 455
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k